Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized phase II trial comparing pazopanib with doxorubicin as first line treatment in elderly patients with metastatic or advanced soft tissue sarcoma

Next Previous
Trial Profile

A randomized phase II trial comparing pazopanib with doxorubicin as first line treatment in elderly patients with metastatic or advanced soft tissue sarcoma

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2018

At a glance

  • Drugs Pazopanib (Primary) ; Doxorubicin
  • Indications Leiomyosarcoma; Liposarcoma; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma; Synovial sarcoma
  • Focus Therapeutic Use
  • Acronyms EPAZ

    • Most Recent Events

    • 05 Jun 2018 Primary endpoint of progression free survival has been met, according to results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 30 Mar 2017 Status changed to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top